CAD and primary effusion lymphoma: To test whether targeting CAD and CDK6 thwarts the progression of KSHV-associated primary effusion lymphomas and potentially virus-negative lymphomas, we treated four lymphoma cell lines, BJAB (KSHV-negative Burkitt-like Lymphoma), as well as PEL cells BC-3 (KSHV-positive), BCBL-1 (KSHV-positive), and JSC-1 (KSHV- and EBV-positive), with PALA, DON, and Palbociclib.